Pfizer Looks to Next-Generation Antibody-Drug Conjugates with CytomX Therapeutics Collaboration
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 6 (Table of Contents)
Published: 24 Jun-2013
DOI: 10.3833/pdr.v2013.i6.1954 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Highlighting its continued interest in the development of antibody-drug conjugates (ADCs), Pfizer has partnered with start-up CytomX Therapeutics to use the company’s Probody™ platform to develop multiple Probody-drug conjugates in oncology...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS